Form 8-K · Current report
Idexx Laboratories 8-K, filed Nov 2, 2026
- Filed
- CIK
- 0000874716
- Accession no.
- 0001104659-26-120892
Summary
IDEXX Laboratories announced third-quarter 2026 financial results, with revenue of $1,214 million up 10% as reported and organic, EPS of $4.01 up 18% as reported, and raised full-year revenue and EPS guidance while lowering its reported operating-margin outlook. CEO Mike Erickson attributed the quarter to commercial execution and innovation, including IDEXX inVue Dx with FNA, IDEXX Cancer Dx as a multi-cancer panel, and the CoVet acquisition.
Key points
- Q3 2026 revenue was $1,214 million, up 10% as reported and organic; Companion Animal Group revenue grew 10% as reported and organic.
- Q3 earnings per diluted share were $4.01, up 18% as reported and 22% on a comparable basis; operating margin was 33.1%, up 100 basis points as reported.
- IDEXX placed over 1,900 IDEXX inVue Dx analyzers during the quarter, bringing the installed base to nearly 11,000 instruments.
- Full-year 2026 revenue guidance was raised to $4,741 million–$4,767 million and EPS guidance to $14.96–$15.16; reported operating margin guidance was lowered to 32.1%–32.3%.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On November 2, 2026, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.